Health Insurance News Astrazeneca S Enhertu Breast Cancer Drug Added To China S State Insurance List
Search Related Content
Sorry, Your Requested Page Was Not Found. Greetings! We apologize for the inconvenience, but the page, Health Insurance News Astrazeneca S Enhertu Breast Cancer Drug Added To China S State Insurance List is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3-18 months after their creation date. We prefer to keep content fresh and current, rather than holding onto outdated news. Thanks for visiting today.Search RobinsPost News & Noticias
Health Canada grants NOC for AstraZeneca’s breast cancer therapy
The decision by the Canadian regulator is supported by the findings from the Phase III DESTINY-Breast06 study. Read More
AstraZeneca hails major breakthroughs with breast-cancer drugs
AstraZeneca showcases three new pioneering drugs at major cancer convention in Berlin. AstraZeneca is enjoying a banner year, averaging a successful phase-three readout every month. The chief ... Read More
AstraZeneca's Datroway extends survival in aggressive breast cancer
Patients with triple-negative breast cancer who were given the drug, Datroway, had a median overall survival of 23.7 months, compared with 18.7 months for those given just chemotherapy. Patients on ... Read More
Enhertu pushes into early breast cancer, as antibody-drug conjugates move up the line
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. BERLIN — Enhertu has become a staple treatment in advanced breast cancer, ... Read More
ESMO: AZ, Daiichi unleash Enhertu's 2-fisted power, aiming to reshape early breast cancer landscape
AstraZeneca and Daiichi Sankyo’s star drug Enhertu has delivered a double knockout, showing its ability to stave off early breast cancer in two pivotal clinical trials. First, in another major head-to ... Read More
Astra, Daiichi post late-stage data to show Enhertu’s potential in early breast cancer
AstraZeneca (NASDAQ:AZN) and partner Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY) on Saturday announced data from two late-stage trials to indicate how their blockbuster antitumor agent Enhertu could be ... Read More
ENHERTU® Reduced the Risk of Disease Recurrence or Death by 53% Versus T-DM1 in Patients with High-Risk HER2 Positive Early Breast Cancer Following Neoadjuvant Therapy in ...
More than 92% of patients treated with Daiichi Sankyo and AstraZeneca’s ENHERTU were free of invasive disease at three years DESTINY-Breast05 presented in ESMO Presidential Symposium I alongside ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus